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Abstract 
 
We here report on non-equilibrium targeted Molecular Dynamics simulations as tool for the 
estimation of protein-ligand unbinding kinetics. With this method, we furthermore investigate the 
molecular basis determining unbinding rates, correlating simulations with experimental data from 
SPR kinetics measurements and X-ray crystallography on two small molecule compound libraries 
bound to the N-terminal domain of the chaperone Hsp90. Within the investigated libraries, we find 
ligand conformational changes and protein-ligand nonbonded interactions as discriminators for 
unbinding rates. Ligands with flexible chemical scaffold may remain longer at the protein target if 
they need to pass through extended conformations upon unbinding, or if they exhibit strong 
electrostatic and/or van der Waals interactions with the target. Ligands with rigid chemical scaffold 
can exhibit longer residence times if they need to perform any kind of conformational change for 
unbinding, while electrostatic interactions with the protein can facilitate unbinding. Our results 
show that understanding the unbinding pathway and the protein-ligand interactions along this path 
is crucial for the prediction of small molecule ligands with defined unbinding kinetics. 
 
Introduction 
 
While rational drug design traditionally focuses on the optimization of binding affinity of 
compounds to target proteins, optimization of target binding kinetics is emerging as a new 
paradigm in drug discovery.1-7 Often, drugs with optimized binding kinetics exhibit better efficacy 
profiles and reduced off-target toxicity,1,8 and thus are more likely to pass later clinical phases.9 
However, while the prerequisites for the rational design of high affinity drugs are well 
investigated,10 the rational optimization of kinetic parameters of small molecules is in its early 
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stages.11,12 Molecular determinants believed to be important in the modulation of binding kinetics 
include ligand molecular size, hydrophobic effects, electrostatic interactions, and conformational 
fluctuations.4,11 Recent reports further highlight the importance of protein-bound water molecules12 
and of protein internal electrostatic interactions.13 However, the exact contribution and extend of 
each of these properties still needs to be further elucidated. 
In order to gain a systematic understanding of the impact of different molecular discriminants on 
binding kinetics, and thus help to establish a knowledge basis necessary for rational design of 
compounds with desired kinetics, we performed a combined experimental and theoretical analysis 
on the dynamics of unbinding of two series of compounds with different chemical scaffolds (see 
Figure 1A) bound to the ATP-binding N-terminal domain of the chaperone heat shock protein 90 
(Hsp90, Figure 1B),14-16 which is a well-known target for anti-cancer drugs.14,17-19 Based on data 
shared within the Kinetics for Drug Discovery consortium (K4DD, www.k4dd.eu)7,20,21 and 
preexisting data sets,19,22,23 we included a total of 26 compounds in the present analysis, which are 
listed in Table S1. Additionally, we determined by X-Ray crystallography the structures of two 
further protein-ligand complexes (see Tables S1 and S3), and measured ligand binding kinetics and 
affinities of three further compounds via surface plasmon resonance (SPR). In detail, we 
investigated fourteen compounds with resorcinol backbone (compounds 1a-1n, see Figure S1; 
amongst them the Hsp90 inhibitor Ganetespib24 1c), ten compounds with N-heterocycle 
functionalities19 (compounds 2a-2k, see Figure S2), and the macrocyclic lactam Hsp90 inhibitor 
17-DMAG18 17. Figure 1B displays an overview of the N-terminal domain of Hsp90 with bound 
compound 1f. The binding site is located close to the protein surface, and exhibits two different 
conformations of the adjacent amino acids 102-114. These residues either form a helix 
conformation (helix 3) or a loop conformation, which was proposed to affect unbinding kinetics.7 
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Figure 1. Comparison of mean non-equilibrium unbinding work (based on n=30 simulations) and 
experimental koff in compound group 1. A: resorcinol (compounds 1a-1n) and N-heterocycle 
(compounds 2a-2k) series scaffolds. B: overview of the N-terminal domain of HSP90 in complex 
with compound 1f. Protein in cartoon, compound 1f in sticks, helix 3 in red, alternate loop 
conformation in yellow. C: different possible protonation states with compound 1a/1aa as example.  
 
 
To assess the molecular mechanisms of unbinding in Hsp90, we performed targeted molecular 
dynamics (TMD) simulations.25-27 In brief, this method uses a holonomic constraint as an additional 
force in the simulations to push the ligand out of the binding site with a constant velocity. The 
constraint force is calculated via a Lagrange’s equation of motion of the 1st kind and updated each 
time step to move the ligand to a position that is in agreement with the preset constant velocity. 
Integrating this force along the pathway yields the work performed to remove the ligand (see 
Supplementary Information for additional details). We focus our analysis on the contributions to 
unbinding kinetics, as unbinding events are easier to calculate than binding events.28 As we almost 
 5 
exclusively use protein/ligand crystal structures with positions of protein-internal water molecules 
being resolved, we have an excellent structural basis for carrying out such simulations. 	
Methods 
 
Chemistry. Information on the synthesis of chemical compounds 1a-1n is provided in patent 
WO2006087077 and in refs. 7,20,29; for compounds 2a-2f, and 2i in published patent applications 
WO2010106290, WO2006123061, WO2008049994 and ref. 19, for compounds 2g and 2h in 
patent WO2006091963, and 2k in patent WO2005028434. LC/MS spectra of the products were 
recorded on an Agilent 1100 HPLC system (1100 high pressure gradient pump, 1100 diode array 
detector) interfaced to an Agilent 1100 mass spectrometer detector using a Chromolith SpeedROD 
RP 18e50-4.6 column. Polar gradient: Water (0.05% HCOOH) - acetonitrile (0.04% HCOOH) 
were used as eluent in mixtures as follows: 0 min, 4% ACN; 2.8 min, 100% ACN; 3.3 min, 100% 
ACN; Gradient: 5.5 min; Flow-rate: 2.4 ml/min; UV detection: 220 nm. 1H NMR spectra were 
recorded at 300 K unless otherwise specified using a Bruker Avance DPX 300, AV 400, DPX 500 
spectrometer (TMS as an internal standard). 1 H NMR chemical shifts are reported in parts per 
million (ppm). 1 H NMR data is reported as chemical shift (dH), relative integral, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, ddd = doublet of doublet of 
doublets, dt = doublet of triplets, td = triplet of doublets, tt = triplet of triplets, qd = quartet of 
doublets) and coupling constant (J Hz). All of the compounds reported in the manuscript have a 
purity ≥95% unless noted otherwise. Analytical data for new compounds is provided in Table S2. 
Crystallization and Structure Determination for compound 2d: A hexa-histidine tagged N-
terminal fragment of Hsp90 (18-223) (NP_005339) was expressed and purified as described in 
ref.	20. Crystallization conditions are also described in ref. 20. Datasets were collected in-house on 
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a Rigaku HF-007 rotating anode generator and a MAR CCD detector and in the synchrotron. 
Diffraction data were processed with either XDS30 or MOSFLM.31 The structures were solved by 
the molecular replacement method using one set of coordinates of N-HSP90 available in the Protein 
Data Bank (pdb code: 1YER). The structures were refined using either CNX,32 REFMAC533 or 
AUTOBUSTER program packages,34 ligands were placed manually, and the structural models 
were manually rebuilt using either TURBO-FRODO (www.afmb.univ-mrs.fr/-TURBO) or 
COOT35. Final validation checks were performed using MOLPROBITY.36 
Crystallization and Structure Determination for compound 2j: A hexa-histidine tagged N-
terminal fragment of Hsp90 (9-236) (NP_005339) was expressed and purified by Instituto de 
Biologia Experimental e Tecnológica (Lisbon, Portugal), according to previously described 
protocols.19 The crystallization conditions are essentially the same as those described in refs. 7 and 
19. Datasets were collected at the SLS synchrotron and processed with the XDS software 
package.30 The structures were solved by molecular replacement with Phaser and refined either 
with CNX7 or BUSTER8. Model building was performed in Coot9, with inhibitors and water sites 
fitted into the initial |Fo|–|Fc| map. Data set statistics for new crystal structures are given in Table 
S3 in the Supplementary Information. 
Surface Plasmon Resonance (SPR) of compounds 2a, 2d and 2j: SPR measurements were 
performed on a Biacore 4000 instrument from GE Healthcare as previously described in refs. 7,20. 
Briefly, recombinant N-HSP90 with 17-Desmethoxy-17-N,N-dimethylaminoethylamino-
geldanamycin ( 17-DMAG, Merck Millipore) was immobilized on a Biacore CM5 chip at 25°C at 
a flow rate of 10 µL/min using amine coupling at pH 4.50 according to Biacore’s standard protocol. 
HBS-N (10 mM Hepes pH 7.40, 0.15 M NaCl) served as the running buffer during immobilization 
and all SPR binding kinetics measurements assays were performed in 20 mM HEPES pH 7.50, 150 
mM NaCl, 0.05% Tween 20, 1 mM DTT, 0.1 mM EDTA, 2% DMSO. Data sets were processed 
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and analyzed using the Biacore 4000 Evaluation software, version 1.1. Solvent corrected and 
double-referenced association and dissociation phase data were fitted to a simple 1:1 interaction 
model with mass transport limitations. 
Simulation setup: TMD calculations were performed with Gromacs v4.6.5 (ref. 37) using the 
AMBER99SB forcefield38,39 for protein and ions, and the TIP3P water model.40 Crystal structures 
for compounds 17 and 1c were taken from PDB IDs 1OSF22 and 3TUH,23 respectively. Structures 
of compounds 2a, 2f and 2i were taken from PDB IDs 2YKC, 2YKI and 2YKJ.19 Due to their high 
similarity, the structure of compound 1f was modeled based on the 1d protein-ligand complex by 
removing a single terminal methyl group of the respective butenyl side chain. Initial structures of 
compounds 2d and 2j were taken from the structures published herein. Crystal structures of all 
other compounds were determined within the Kinetics for Drug Discovery consortium and are 
published in refs. 7,20,21 (see Table S1). Ligand parameters were created with antechamber41 and 
acpype42 using GAFF parameters and AM1-BCC charges.43,44 Protein/ligand crystal structures 
together with present crystal water molecules were centered in a cubic box with 7 nm side length, 
missing protons added, protonated, solvated, and sodium ions added to ensure a charge neutral 
simulation box. Protonation states of amino acids were determined by propka.45 Ligand charge 
states were selected according to literature pka values.46,47 In case of compounds 1j and 2a-k, in 
which protonable nitrogen atoms are found close to Asp93 and thus potentially could exhibit a 
different pka due to formation of salt bridges and/or strong hydrogen bonds, we performed QM 
calculations to obtain the correct protonation state: following earlier works,46 we extracted the 
Asp93 side chain, appropriate ring fragments of the ligands carrying the protonable nitrogen atoms 
and water molecules between ligand fragments and the Asp93 side chain. In addition, we extracted 
a water molecule far from the binding site to carry an excess proton to keep the QM box charge 
neutral if necessary. Applying position constraints to atoms linking the extracted fragments to the 
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removed backbone and side chains as well to the additional water molecule in such a way that their 
orientation remained close to crystal structures, we then optimized the QM systems subsequently 
at the HF/6-31G*, HF/6-31++G** and B3LYP/6-31++G** level using Orca.47 For compounds 2a-
2k, if the ligand fragment was capable to protonate Asp93, we chose the deprotonated form of the 
ligand, otherwise the protonated form. The list of resulting protonation states is given in Table S1. 
For compound 1j, which does not exhibit a direct salt bridge with Asp93, we chose the protonated 
form due to a lower final total system energy. 
TMD calculations: Simulations were carried out with PME48 for electrostatics (minimal real space 
cut-off of 1 nm) and a van der Waals cut-off of 1 nm. Hydrogen atom bonds were constrained via 
the LINCS49 algorithm. The prepared systems were first minimized with the conjugate gradient 
method, and subjected to a short equilibration runs in the NPT ensemble at 300 K and 1 bar, using 
the Berendsen thermostat and barostat,50 with an integration step size of 2 fs and a trajectory length 
of 100 ps. For each ligand, 30 statistically independent equilibration runs were performed, in which 
differed velocity distributions were attributed to the minimized systems. Non-equilibrium TMD 
calculations using the Gromacs PULL code in constraint mode were then carried out by continuing 
the 30 independent equilibration runs for 200 ps in the NPT ensemble at 300 K and 1 bar, using 
the Nosé-Hoover thermostat51,52 and Parrinello-Rahman barostat,53 with a fixed constraint velocity 
of 0.01 nm/ps and an integration step size of 1 fs. Constraint pseudoforces were written out for 
each time step. The 1st reference group for COM pulling along path 1 consisted of all C(alpha) 
atoms of the beta-sheet forming the ligand binding site (see Fig. S3) and of all C(alpha) atoms of 
helix 1 for path 2, the 2nd group was formed by the ligand heavy atoms. Trajectory evaluation was 
then carried out with Gromacs tools, and data evaluation in Python using numpy and scipy 
libraries.54 
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Thermodynamic integration55 simulations were performed by extracting 21 equidistant snapshots 
from a random non-equilibrium simulations, and carrying out equilibration simulations of 10 ns 
trajectory length with them, setting the constraint velocity to zero (for a detailed explanation see 
Ref. 56). Mean constraint pseudoforces were taken from the last 2.5 ns of these simulations. Free 
energy profiles as given in Fig. S4A were then calculated by integrating the mean forces along the 
distance from the binding site x. 	
Results & Discussion 
 
A linear non-equilibrium energy relationship for unbinding kinetics. At the beginning of our 
investigations, we attempted to characterize the ligand unbinding kinetics of Hsp90 ligands by 
determining their free energy profile along the unbinding pathway via standard stationary 
Thermodynamic Integration55 (TI) calculations. The most probable unbinding pathway for the 
ligand appeared to be the passage through an opening between helices 1 and 3 (pathway 1 in Figure 
S3). Figure S4A displays the resulting free energy surface for compounds 1b, 1g, and 1l, which is 
in good general agreement with free energy curves for other Hsp90 binding ligands obtained by 
umbrella sampling.29 The three investigated compounds exhibit 1-2 free energy barriers between 
the ligand bound and unbound state. Interpreting the shape and peak height by means of the Eyring 
equation57 for rate constants, 
,          (1) 
with the friction-dependent prefactor k, the inverse temperature b = 1/RT and the free energy 
difference between bound state and unbinding transition state DG≠, we find a good qualitative 
agreement with the respective koff constants: 1l effectively does not exhibit a barrier, but a slope 
between bound and unbound state, and consequently exhibits the fastest unbinding of the three test 
koff =κ exp −βΔG≠( )
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compounds. 1b and 1g exhibit a comparable transition barrier of ca. 65 kJ/mol (Figure S4). 
However, the barrier of 1b is broader than the one of 1g, and its maximum is found at 0.7 nm vs. 
0.65 nm for 1g. Furthermore, 1b possesses a 2nd small barrier at 1.8 nm. 1i should therefore unbind 
faster than 1l, but slower than 1b. These overall shapes are in good agreement with the experimental 
observation that 1b is exhibits the slowest unbinding of the three test compounds (see Table S1). 
The main problem we faced when applying stationary TI calculations was the large number of 
necessary equilibration points along the unbinding pathway that need several nanoseconds of 
equilibration for reliable determination of the free energy surface,58 significantly raising the 
computational cost for investigating a large set of compounds. Furthermore, in our two investigated 
compound groups, about half of all compounds exhibit two possible protonation states (1a, 17, 1j 
and the full series 2). As an example, the morpholine side chain in 1aa (pKa ≈ 10)59 can exist in a 
protonated state with a charge of +1 e (see Figure 1C), or in a deprotonated state 1a with a charge 
of 0 e. All ligands in compound group 2 are bound to the protein by a hydrogen bond between 
nitrogen atoms in aromatic rings (pka range of ca. 3-5)60 and Asp93 (see Figure S5), or via highly 
polarized water molecules mediating this contact.61 Assigning the correct protonation state for such 
protein-ligand-water complexes is a challenging task, as the protein environment can significantly 
alter pKa values.61,62 To avoid a bias from wrongly chosen charge states, we needed a method that 
allowed us to carry out simulations of multiple compounds in 2-3 possible protonation states, with 
TI calculations simply being too inefficient for this task.  
Surprisingly, when we looked at the mean non-equilibrium work profiles <W> from simulations 
necessary to generate start coordinates for TI calculations (see Figure S4B), we found that the 
difference in <W> at the end of simulations qualitatively matches the order of unbinding constants 
of compounds 1b, 1g, and 1l. Furthermore, we observed that differences in <W> between 
compounds (Figure S4C) appear at positions where the DG curve from TI exhibits local maxima. 
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Furthermore, <W> converges rapidly within already n=30 independent trajectories (see Figure S6). 
We thus evaluated a possible correlation between non-equilibrium TMD work <W> and 
experimentally determined koff constants using the full investigated compound set comprising all 
possible protonation states, as displayed in Figure S7A. As in the case with compounds 1b, 1g, and 
1l, we observe a qualitative agreement between <W>(TMD) and koff, that appears to follow a linear 
dependency,	with ligands requiring a large <W> being slowly unbinding compounds. Such a linear 
dependence can be expected for equilibrium ∆G≠ in form of a linear free energy relationship,63 but 
is surprisingly present in our non-equilibrium simulations, as well, and points to a connection 
between non-equilibrium work and the underlying equilibrium free energy profile. According to 
the Jarzynski equality,64 
           (2) 
with dissipative work Wdiss. Based on the mentioned increase of <W> at transition states ∆G≠ (cf. 
Figure S4C) and taking into account that we perform simulations in deep non-equilibrium (<W> is 
much larger than DG), we postulate that we do not observe system relaxation after crossing over 
the transition states, and thus 
.           (3) 
Introducing Equation (3) in (1), we obtain 
          (4) 
with , which serves as a basis of understanding the apparent linear non-
equilibrium energy relationship. C effectively is a function of b, but in the following is treated as 
an independent fit factor, as we otherwise encountered instabilities in non-linear curve fitting. In 
the following, we approximate C to be constant, which is only valid in the case that the friction 
during unbinding is the same for all ligands. 
ΔG = W −Wdiss
ΔG≠ ≈ W −Wdiss
W = −β−1 ln koff +C
C = β−1 lnκ +Wdiss
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Figure 2. A: Comparison of experimentally derived koff constants and calculated TMD work <W>. 
Error bars indicate the standard error of the mean (SEM): vertical lines for n=30 simulations, 
horizontal lines for n=2-4 measurements. The data can be rationalized as the co-existence of two 
populations with different linear offset (blue and green, respectively). The red population is formed 
by helix-binding compounds, the blue population by loop-binding compounds. Alternate 
protonation states of the ligands (crosses) lead to lower values in non-equilibrium work. Additional 
compound 17a (black) is in better agreement with helix- than with loop-binding resorcinol 
compounds. Comparison of <W>(TMD) and experimental koff for compounds 2a to 2k in cyan. 
All possible protonation states displayed as cyan crosses, protonation stated predicted by QM 
calculations as red corsses. Choice of states that give an optimal linear regression according to 
Equation (4) in cyan diamonds. Error bars indicate the standard error of the mean (SEM): vertical 
lines for n=30 simulations, horizontal lines for n=2-4 measurements. B: Receiver operating 
characteristic (ROC) curves and area under curve (AUC) for <W>(TMD) as predictor for 
unbinding kinetics. Coloring according to A. For group 1 compounds, <W>(TMD) is a good 
predictor for koff after separation into helix- and loop-binding compounds. For group 2 compounds, 
<W>(TMD) is a weak predictor after separation according to optimal linear regression states.  
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We proceeded carrying out TMD simulations in strict non-equilibrium with the full compound 
groups 1 and 2, with protonation states derived from literature59,60 or QM calculations (cf. Methods 
for details and Figure S1 and S2 for an overview of all employed ligand structures), and used the 
resulting mean work <W> as unbinding scores.56 Fitting Equation (4) to the full data set on non-
equilibrium works <W> as displayed in Fig. S7A, we again observe a qualitative agreement 
between <W> and experimental koff that can be rationalized as a linear dependency, although with 
a low Pearson’s correlation coefficient of R2 = 0.39. It appears that for the full set of compounds, 
assuming C in Eq. (4) to be constant is not a good approximation. We thus searched for 
physicochemical, reasonable categories within the initial data. Based on differences in helix-ligand 
and loop-ligand contact dynamics,65 we separated the compounds according to helix- and loop-
binding compounds (see Fig. S7B), resulting in an improved R2 = 0.59 for loop-binding compounds, 
but at an expense of R2 = 0.18 for helix-binding compounds. We further separated the sets 
according to protein conformations into compound sets 1 (only taking resorcinol scaffolds into 
account) and 2 as displayed in Fig. S7C. In the case of group 1 compounds, this improved the R2 
= 0.80, and lead to a moderate R2 =0.54 for loop-binding compounds. Series 2 does not experience 
the split, as all contained compounds bind to the helix conformation. Fitting Equation (4) to this 
series however resulted only in a low R2 = 0.39. To achieve a better agreement of Equation (4) and 
<W>(TMD) for group 2, we postulate that some of the protonation states used in our calculations 
either are not correctly predicted by our QM calculations or change during unbinding due to 
transient protonation state changes. By iterative exclusion of states, which contain the largest 
residual (i.e. are farthest apart from the fit model), we searched for a combination of data points 
that follows equation (4) and yields a maximal R2. The results are presented in Figure 2A and S7C: 
the postulate significantly improved the agreement between theoretical results and our theoretical 
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model (R2 = 0.87). We thus propose that the protonation state of a given compound during 
unbinding may be inferred as the state, which is in best agreement with the linear regression in the 
<W>-koff correlation of the whole compound series. 
To assess if <W>(TMD) is a suitable score for a small koff, we calculated receiver operating 
characteristic (ROC) curves characterized by the respective area under curve (AUC) for the given 
data set.66,67 While the application to both full and protein conformation-separated data set yielded 
only random results (AUC ≈ 0.5), resorcinol compounds 1 after conformation separation resulted 
in a moderate to good prediction of slowly unbinding compounds (AUC = 0.72 for loop compounds 
and 0.81 for helix binding compounds). However, in the case of compound group 2, <W>(TMD) 
is a bad predictor, while it is slightly improved over random selection for the optimal linear fit 
selection of ligands (AUC = 0.64). In this respect, <W>(TMD) faces similar problems with scaffold 
dependency like common affinity prediction-oriented docking,68 but may indeed serve as a pre-
selection criterion for slow unbinding compounds for suitable targets and ligands. 
As all the calculations reported above took only unbinding along path 1 into account, we needed 
to assess if other possible unbinding pathways exist. Kokh et al. showed that two routes out of the 
binding site of the Hsp90 N-terminus exist,20 the first one being path 1, and the second being found 
between helix 3 and the central b-sheet (path 2 in Fig. S3). Testing both pathways with 1a and 
2a/2aa, we found that path 1 requires significantly less work for pushing the ligand into the solvent 
than path 2 (see Table S4), making it the most likely unbinding pathway. Furthermore, this pathway 
leads past Leu107, which has been implicated by point mutation experiments to affect unbinding 
kinetics. 7 
 
Influence of protein conformation and electrostatics on group 1 unbinding rates. As a starting 
point for investigating molecular effects influencing unbinding rates, we focused on a dependence 
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on helix/loop 3 conformation as implied by our analysis in Fig 2. For helix binding compounds it 
was proposed that entropic contributions from protein flexibility play a significant role in the 
determination of binding affinities.7 Indeed, helix binding compounds with decreasing koff display 
an increasing unbinding <W>, which can be interpreted as stronger resistance from the protein 
against the constraint force acting on ligands, correlating with a decreased protein flexibility.  
As can be seen in Fig. 2, the protonated ligand 17a and 1ja result in a slightly higher <W> than the 
neutral forms. This finding is consistent with the structure of the protein/ligand complexes, e.g., as 
the resulting ammonium moiety in 17a is found close to Asp54 (see Fig. S8), allowing the 
formation of a salt bridge (N–O distances of 2.8 Å). Indeed, enthalpic contributions comprising 
electrostatic interactions were found to be key factors in determining koff in loop binders.7 However, 
the presence of a charge on the protein does not necessarily lead directly to an increased koff, as can 
be seen in the case of compound 1a: here, both charged state 1a and neutral state 1aa exhibit a 
comparable <W> due to an increased distance of 4.7 Å between Asp54 and the protonable 
morpholine moiety in 1a (Figure S9). We conclude that within our investigated compound set, 
ligand charge slows down unbinding kinetics in loop binding compounds.  
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Figure 3. Influence of ligand radius on unbinding kinetics of the resorcinol series compounds. 
Group 1 helix binders in red, loop binders in blue, group 2 in cyan. Linear regression of full data 
as full lines, fits excluding outliers as dashed lines. Line colors match the color of data points used 
for fits. A: integral of radii of gyration difference to unbound state integrated over pulling distance. 
Helix binding compounds that bind in an extended conformation may unbind slowly (R2 = 0.30). 
For loop binders, this connection is not present. B: average radii of gyration in unbound state (last 
quarter of simulation). Loop-binding compounds unbind slowly if they are large (R2 = 0.63). C: 
absolute integral of radii of gyration difference to unbound state over the full course of simulation. 
Protonation states predicted by QM calculations as red crosses. Choice of states that give an optimal 
linear regression according to Equation (4) in cyan diamonds. In the N-heterocycle compound 
series 2, unbinding kinetics of slowly unbinding compounds appear to be coupled to the amount of 
absolute changes of ligand radius (R2 = 0.60, taking 2i, 2j and 2k as outliers). Rigid ligands unbind 
slowly, while molecules that apparently can pass through either extended or contracted 
conformations unbind fast.  
 
Impact of resorcinol conformation on unbinding kinetics. Having identified electrostatic 
interactions between protein and ligand as discriminator for ligand unbinding kinetics, we 
performed an analysis of ligand conformational changes during unbinding. We used the ligand 
radius of gyration as observable, i.e., the average distance of all ligand atoms from their common 
center of mass, and compared the different radii with the natural logarithm of the experimentally 
determined koff. For helix-binding compounds shown in Fig. 3A, we obtain a weak linear 
correlation (R2 = 0.30) between differences in radii during unbinding and the average radii in the 
unbound state (i.e., during the 4th quarter of the simulation): compounds, which bind to the protein 
in or need to pass through an extended conformation appear to unbind slowly. This result can be 
rationalized as an entropic contribution to unbinding kinetics: the conformational space of flexible 
ligands becomes restricted during unbinding, which causes an entropic penalty, turning unbinding 
less probable. 
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In loop conformation binding compounds (Figure 3B), the overall radius of gyration (calculated 
for the unbound state) may decide the unbinding rate, though the agreement between linear fit and 
actual data again is weak (R2 = 0.63). Compound 1a is significantly larger than the remaining loop 
binders. Loop-binding compounds appear therefore to unbind slowly if they exhibit strong van der 
Waals interactions with the protein, which again is in agreement with the importance of enthalpic 
contributions for loop binders. We note that the hypotheses listed in the previous two paragraphs 
need to be taken with a grain of salt, as they are only weakly supported by our data, and mostly 
depend on a single data point (1n for helix binders and 1a for loop binders).  
Ligand charges and conformation effects in compound group 2. Figure 3C shows that for the 
N-heterocycle series 2, the best agreement between radii of gyration changes and experimental 
unbinding constants for slowly unbinding compounds (i.e., when ignoring compounds 2i, 2j and 
2k) is found for the absolute change in radius of gyration (their exclusion increases R2 from 0.37 
to 0.60). Such outliers may be related to the large variation of side chains within the series, and 2j 
and 2k exhibit a unique scaffold. In other words, slowly unbinding compounds from group 2 appear 
to be rigid structures, while fast unbinding compounds can change their conformation, irrespective 
of if they pass through extended or contracted states. Although the binding mode of series 1 and 2 
helix binders is quite similar (cf. Figure S5), the source of this difference lies in the individual 
flexibilities of scaffolds: the resorcinol scaffold is branching off the variable side chains at an angle 
of 120˚ with a low distance between branching points, and the series contains several flexible side 
chains, leading to a wide range of conformations that they can access. The N-heterocycle 
compounds are based on large and rigid scaffolds (fluorenyl and indazole moieties), which holds 
true for side chain moieties, as well. Series 2 compounds therefore are enthalpically locked in their 
conformation, and either extending or contracting their overall radius will be energetically 
unfavorable. We therefore conclude that the detailed connection between conformational changes 
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and unbinding kinetics for the investigated Hsp90 ligands is dependent on the individual 
conformational space accessible by a ligand. 
 
Figure 4. Electrostatic facilitation in compound 2f. A: radius of gyration as average of n=30 
simulations. Trajectory mean as lines, SEM as shaded area. Uncharged ligand 2f in red, protonated 
form 2fa in yellow. The overall change in ligand radius during unbinding along the unbinding path 
is smaller in the charged state than in the uncharged state. B: molecular details of ligand unbinding. 
The reason for the smaller changes in radius of gyration during unbinding is a favorable charge 
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interaction of the azaindoline moiety with Asp102, which facilitates the contraction of the ligand 
from (1) to (2), and guides the ligand out of the binding pocket, allowing a faster transition into the 
unbound conformation (3).  
 
Electrostatic locking vs. facilitation. Having identified this specificity in conformational changes, 
we observe a different impact of ligand charge for compound group 2 in contrast to the series 1: as 
can be seen in in Figure 2C, in the case of compounds 2a, 2c, 2e-g and 2i-k, neutral ligands exhibit 
a higher <W> than the protonated ligands with positive charge. Figure 4 displays the effect of 
molecular charges for the unbinding pathway of 2f: In the uncharged state, 2f needs to stay in a 
more contracted conformation until a distance of 1.5 nm from the initial binding position. In the 
case of the protonated state 2fa, a favorable charge interaction of the azaindole moiety with Asp102 
occurs, which allows a faster transition to the radius of gyration of the unbound state, which is 
already reached at a distance of 1.0 nm from the initial binding position, i.e., when the ligand is 
only partially unbound. The positive charge on the ligand thus facilitates the contraction of the 
ligand and guides it out of the binding pocket. We note that this facilitation of unbinding by 
transient electrostatic interactions is directly connected to the scaffold-inherent flexibility 
restrictions within compound group 2. As mentioned above, we propose that protonation state 
switches of individual ligands may appear transiently, as well, so that the protonation state 
predicted by the linear regression of Equation (4) does not necessarily agree with the protonation 
state predicted from pka calculations. 
Performance of non-equilibrium TMD. In recent years, several other novel methods have been 
established for fast and efficient computation of binding kinetics12,20,66,70-72 (see refs. 73,74 for 
reviews), and our approach presented here shares similarities with methods based on 
metadynamics12 and steered MD.69 As a prerequisite, we need to have initial information on 
unbinding pathways to create a suitable reaction coordinate to apply the target bias, as can be 
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provided by other methods.20,66,75 It was recently shown that TMD simulations can be used to 
effectively push a molecular system of choice along a reaction coordinate that correctly mimics the 
pathway taken under equilibrium conditions.56 Besides the results presented here, we found that 
proteins with challenging unbinding pathways pose a problem for our non-equilibrium TMD 
method, as a similar investigation with ligands bound to the b2 adrenergic receptor70 performed by 
us did not succeed in obtaining a successful linear non-equilibrium energy relationship (data not 
shown). The reason for this appears to be the presence of a second intermediate ligand binding 
site71 that increases the complexity of the underlying free energy surface and the resulting ligand 
diffusion kinetics, and other approaches72 may face similar challenges. The first major strength of 
our non-equilibrium method is the significant reduction of necessary computational power: 
unbinding can be enforced within 0.1 to 0.3 ns simulated time, which allows us to reduce the 
necessary calculation time by a factor of 30 in comparison to stationary TI73 (180 CPUhs for one 
non-equilibrium unbinding event sampled with 30 trajectories vs. 6000 CPUhs for one equilibrium 
free energy pathway analyzed by 20 intermediate steps on a recent octacore CPU workstation). 
Secondly, the non-equilibrum work rapidly converges (see Figure S6),58 and each simulation by 
definition results in an unbinding event, which reduces the necessary number of simulations to a 
number well below that for Markov State Model creation.74 Thirdly, we do not change the full 
system Hamiltonian, but merely add a perturbation, avoiding artifacts such as protein unfolding 
that appear in smoothed/scaled MD.72,75 The last strength is that according to the works of 
Jarzynski,64 <W> is directly related to the free energy along the pathway, as shown in equation (2). 
This connection allows the development of methods to directly calculate the equilibrium free 
energy profile during unbinding from non-equilibrium simulations,58 which we will use in the 
future to investigate the predictions from our linear model given in Equation (4) concerning 
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different dissipation profiles and the individual protonation states of ligands along the unbinding 
pathway. 
 
Conclusion and future perspective 
 
To elucidate the molecular determinants for unbinding kinetics, we here combined preexisting and 
novel data from SPR binding kinetics measurements and X-ray crystallography with non-
equilibrium targeted MD simulations on the N-terminal domain of Hsp90 for two compound series. 
The non-equilibrium work <W> obtained from TMD simulations converges quickly, and is a 
promising predictor for slowly unbinding compounds. We found ligand conformational changes 
and nonbonded protein-ligand interactions as molecular discriminators for unbinding rates. The 
exact impact of these two contributions depends on individual ligand scaffolds and the details of 
transient protein-ligand interaction during unbinding. Ligands within the investigated series with 
flexible chemical scaffold and side chains may remain longer at the protein target if they need to 
pass through an extended conformation upon unbinding. Ligands with rigid chemical scaffold and 
side chains stay longer at the protein target if they need to perform any conformational change for 
unbinding at all. Electrostatics exhibits a dual effect onto unbinding kinetics: the presence of a 
charge can increase the residence time of compounds 1 with a flexible scaffold by locking it to the 
protein, which appears to be also the case for increased van der Waals interactions. In the case of 
compounds 2 with a rigid chemical scaffold, electrostatics can accelerate unbinding by facilitating 
the formation of a contracted form and guiding the ligand out of the binding pocket. Extrapolating 
our results to the rational drug design in general, we thus propose that clear knowledge of the 
conformational space accessible by the ligand, the exact unbinding pathway, and the transient 
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protein-ligand interactions along this path are important prerequisites for the prediction of ligands 
with favorable unbinding kinetics. 
As our interpretation of the mean non-equilibrium work <W> as score for koff by use of Equation 
(4) is based on the Jarzynski equality,64 we potentially can calculated the unbinding free energy 
profile directly from <W>. Indeed, we recently showed for a NaCl/water test system that such a 
correction can readily be achieved via dissipation-corrected targeted MD simulations.58 As this 
approach additionally yields friction profiles, we will aim to use the resulting information to carry 
our Langevin Dynamics calculations76 for the prediction of absolute ligand unbinding kinetics. 
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Table S1. List of compounds, dynamic properties and protein conformations of investigated compounds.  
compound Ref. for 
kinetics and 
affinity 
koff / 
s-1 
KD / 
M-1 
kon / 
M-1 s-1 
helix 3 
conf. 
PDB ID with 
ref. 
protonation 
state by pka 
(see Figs. S1 
& S2 
1a 2 <1.00E-04 <1.00E-09 (n.d.) loop 5NYI1 1aa 
17 (17-DMAG) 1 3.00E-04 4.57E-09 (n.d.) loop (out) 1OSF2 17a 
1b 1 3.30E-04 
±2.1E-05 
4.60E+05 
±4.0E-11 
2.15E+05 
±5.40E+04 
helix 5J203 1b 
1c (Ganetespib) 1 5.70E-04 1.00E-09 (n.d.) loop 3TUH4 1c 
1d 1 1.70E-03 
±4.6E-04 
2.30E-08 
±4.4E-09 
7.00E+04 
±7.50E+03 
helix 5J9X3 1d 
1e 1 1.79E-03 
±4.7E-06 
3.81E-09 
±3.5E-10 
4.72E+05 
±4.10E+04 
helix 5J863 1e 
1f 1 4.20E-03 
±5.2E-04 
2.40E-08 
±1.0E-09 
1.80E+05 
±2.50E+04 
helix Modelled 
from M5 
1f 
1g 1 6.40E-03 
±4.3E-04 
8.70E-08 
±2.1E-09 
7.70E+04 
±1.20E+04 
helix 5J271 1g 
1h 1 1.40E-02 
±2.2E-03 
2.66E-08 
±2.6E-09 
5.20E+05 
±1.30E+05 
loop 5J2X3 1h 
1i 1 1.40E-02 
±1.5E-03 
4.30E-07 
±6.1E-08 
3.30E+04 
±1.30E+03 
helix 5J861 1i 
1j 1 3.38E-02 
±1.13E-03 
7.11E-08 
±4.327E-9 
4.79E+05 
±1.65E+04 
loop 6FCJ5 1ja 
1k 2 6.34E-02 
±3.5E-03 
5.14E-07 
±6.0E-09 
1.23E+05 
±5.23E+03 
loop 6ELO1 1k 
1l 2 1.74E-01 
±2.2E-02 
2.36E-07 
±1.9E-08 
7.42E+05 
±1.53E+05 
helix 6ELP1 1l 
1m 1 2.10E-01 
±3.3E-02 
1.80E-07 
±1.2E-08 
1.20E+06 
±2.10E+05 
loop 5J643 1m 
1n 2 2.54E-01 
±1.8E-02 
9.00E-07 
±1.7E-08 
2.80E+05 
±1.47E+04 
loop 6ELN1 1n 
2a (here) 7.10E-05 7.74E-09 (n.d.) helix 2YKC6 2a 
2b 2 1.36E-04 
±3.8E-06 
8.48E-09 
±6.9E10 
1.62E+04 
±1.78E+03 
helix 5LQ91 2b 
2c 2 1.89E-04 
±7.1E-05 
4.66E-08 
±2.5E-08 
4.77E+03 
±1.35E+03 
helix 5LR71 2ca 
2d (here) 1.94E-04 1.01E-08 (n.d.) helix 5LRL (here) 2da 
2e 2 2.78E-04 
±4.65E-06 
1.72E-07 
±1.2E-07 
3.06E+03 
±2.09E+03 
helix 5LRZ1 2e 
2f 2 2.85E-04 
±4.9E-05 
3.61E-08 
±5.7E-09 
7.77E+03 
±1.48E+02 
helix 2YKI6 2fa 
2g 2 4.85E-04 
±1.39E-04 
3.95E-09 
±1.7E-09 
1.33E+05 
±2.37E+04 
helix 5LS11 2g 
2h 2 7.65E-04 
±5.0E-05 
2.40E-10 
±8.9E-11 
3.58E+06 
±1.11E+06 
helix 5T211 2h 
2i 2 9.89E-04 
±1.3E-04 
9.50E-08 
±4.5E-09 
1.04E+04 
±9.04E+02 
helix 2YKJ6 2iba 
2j (here) 3.697E-03 
±1.5E-05 
3.285E-8 
±5.61E-9 
1.17E+05 
±1.49E4 
helix 5LO1 (here) 2ja 
2k 2 2.56E-02 
±1.4E-02 
2.47E-08 
±6.5E-09 
1.26E+06 
±8.78E+05 
helix 5LR11 2k 
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Table S2. Analytical data 
# LC-MS 1H NMR 
1j 
M+H [m/z] 287.08 
1H NMR (250 MHz, DMSO-d6) δ 9.43 (s, 
1H), 9.41 (s, 1H), 7.67 (d, J = 1.8 Hz, 1H), 
7.54 – 7.48 (m, 1H), 7.45 – 7.33 (m, 3H), 
6.71 (d, J = 8.3 Hz, 1H), 6.41 (d, J = 1.8 Hz, 
1H), 6.23 (d, J = 2.3 Hz, 1H), 6.09 (dd, J = 
8.4, 2.4 Hz, 1H). 
2j 
M+H [m/z] 415.90 
1H NMR (500 MHz, DMSO-d6) δ 7.71 (dd, 
J = 8.9, 2.2 Hz, 1H), 7.65 – 7.60 (m, 2H), 
7.50 (d, J = 8.9 Hz, 1H), 7.47 – 7.44 (m, 
1H), 7.36 – 7.31 (m, 1H), 7.31 – 7.26 (m, 
1H), 7.26 – 7.23 (m, 1H), 7.21 – 7.01 (m, 
2H), 4.99 (s, 2H), 4.67 (s, 2H), 3.00 – 2.93 
(m, 2H), 2.70 – 2.63 (m, 2H), 2.35 – 2.28 
(m, 2H), 1.84 – 1.69 (m, 2H), 0.85 (t, J = 
7.2 Hz, 3H). 
 
  
 34 
Table S3. Data collection and refinement statistics  
  2d 2j 
Data collection   
Space group I222 I222 
Cell dimensions   
  a, b, c (Å) 66.46 90.7 98.53  65.86 92.36 97.11 
  α, β, γ (°) 90.00, 90.00, 90;00 90.00, 90.00, 90.00 
Resolution (Å) 
36.36-1.33 (1.33-
1.40) 
48.56-2.70 (3.02-2.70) 
Nr. observations  
245593 50496  
Unique reflections 
63093 8553 
Redundancy 
4.6 (3.3)  
Completeness (%) 91.8 97.6 
Rmerge (%)d 5.2 (23.1) 5.4 (29.5) 
I/σ(I) 14.8 (1.8) 17.2 (2.9) 
Refinement   
Resolution (Å) 66.73 48.56-2.67 
Rwork (%) 17.4 23.3 
Rfree (%) 18.9 24.6 
Model composition 
and completeness 
  
  Protein 1638 1524 
 35 
  Ligand 33 31 
  solvent 354 17 
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Table S4. Statistics for ligand pulling via path 1 and path 2 (see Figure S3). Errors indicate SEM (n = 30). 
compound <W> along path 1 / kJ/mol <W> along path 2 / kJ/mol 
1b 578 ± 8 974 ± 23 
2a 550 ± 14 659 ± 12 
2aa 508 ± 11 717 ± 19 
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Figure S1. Resorcinol compound group 1 with additional compound 17 (17-DMAG). 1aa and 17a and 
1ga represent alternative protonoation states of 1b and 1g, respectively. 
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Figure S2. N-heterocycle compound group 2. Compound names with two letters denominate alternative 
protonation states. 
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Figure S3: Definition of reaction coordinates in TMD runs. 
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Figure S4: Free energy profile ∆G (A) and non-equilibrium work <W> (B) for compounds 1b, 1g, and 1l 
calculated via thermodynamic integration7 and non-equilibrium TMD. C: differences of <W> referenced 
to 1l. The shaded surfaces represent the SEM (n=30).   
 41 
 
Figure S5: comparison of binding mode of resorcinol compound 1d and N-heterocycle compound 2c. 
Hydrogen bonds displayed as red dashes. 
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Figure S6: Convergence of non-equilibrium work <W> in dependence to the number of averaged 
trajectories for selected resorcinol compounds (“blue” population in Fig. 1). The work appears to be 
converged after ca. 25 averaged trajectories.  
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Figure S7: Model building for rationalization of non-equilibrium work and kinetic data. Error bars 
indicate the SEM (n=30 for <W> and 2-4 for koff). A: fit to full data set, i.e., all compounds. B: separation 
into helix- (red) and loop-binding compounds (blue). Additional compound 17a in black. C: separation 
into ligand scaffolds. Resorcinol loop- and helix-binding compounds in blue and red, respectively. 
Additional compound 17a in black. N-heterocycle compounds (group 2) in cyan. All possible group 2 
protonation states displayed as cyan crosses, protonation stated predicted by QM calculations as red 
corsses. Choice of states that give an optimal linear regression according to Equation (4) as cyan 
diamonds. 
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Figure S8. Charge interaction of compounds 17a and 1aa with Hsp90. Hydrogen bonds displayed as red 
dashes. 
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